biostudies-literatureUnknownVandebergh MNIA NIH HHSNIMH NIH HHSNINDS NIH HHS<h4>Background and objectives</h4><i>TMEM106B</i> has been proposed as a modifier of disease risk in FTLD-TDP, particularly in <i>GRN</i> mutation carriers. Furthermore, <i>TMEM106B</i> has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study is to evaluate and compare the effect of <i>TMEM106B</i> on gray matter volume and cognition in each of the common genetic FTD groups and in sporadic FTD patients.<h4>Methods</h4>Participants were enrolled through the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study, which includes symptomatic and presymptomatic individuals with a pathogenic mutation in <i>C9orf72, GRN, MAPT, VCP, TBK1, TARDBP</i>, symptomatic non-mutation carriersmedRxiv : the preprint server for health sciences2024.04.05.24305253https://www.ebi.ac.uk/biostudies/studies/S-EPMC11023674biostudies-literatureGene specific effects on brain volume and cognition of &lt;i&gt;TMEM106B&lt;/i&gt; in frontotemporal lobar degeneration.PMC11023674U01 NS100610R25 NS098999R21 NS114764U54 NS092089U01 NS080818P30 AG062429U24 AG021886R01 AG038791P30 AG072977U01 AG045390U01 AG079850K23 AG061253R01 AG062268R01 MH120794U19 AG063911Kornak JRademakers RRamos EMGrant IMClark DRosen HJGhoshal NOnyike CLitvan IDomoto-Reilly KKwan JYPetrucelli LWynants SWint DDickerson BCPascual BGendron TFBarmada SLeger GCFields JARitter ACorriveau-Lecavalier NIrwin DTartaglia MCGalasko DRBozoki AKolander TSullivan ACHsiung GRVan den Broeck MGeschwind DRoberson EDSnyder AForsberg LKHuey EDAppleby BHonig LSWolf ABaker MCBoxer ALBoeve BFPressman PDarby RRBorrego-Ecija SGraff-Radford NKnopman DSVandebergh MRamanan VKMendez MFMester CBrushaber DMasdeu JCStaffaroni AMHeuer HWKantarci KfalseGene specific effects on brain volume and cognition of &lt;i&gt;TMEM106B&lt;/i&gt; in frontotemporal lobar degeneration.<h4>Background and objectives</h4><i>TMEM106B</i> has been proposed as a modifier of disease risk in FTLD-TDP, particularly in <i>GRN</i> mutation carriers. Furthermore, <i>TMEM106B</i> has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study is to evaluate and compare the effect of <i>TMEM106B</i> on gray matter volume and cognition in each of the common genetic FTD groups and in sporadic FTD patients.<h4>Methods</h4>Participants were enrolled through the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study, which includes symptomatic and presymptomatic individuals with a pathogenic mutation in <i>C9orf72, GRN, MAPT, VCP, TBK1, TARDBP</i>, symptomatic non-mutation carriers2024-01-01T00:00:00Z2024 Apr2026-06-11T03:19:44.308Z2026-06-11T03:13:00.317ZS-EPMC110236743863378410.1101/2024.04.05.24305253